Skyrizi vs. Cosentyx

• Are Skyrizi and Cosentyx the Same Thing?
• What Are Possible Side Effects of Skyrizi?
• What Are Possible Side Effects of Cosentyx?
• What Is Skyrizi?
• What Is Cosentyx?
• What drugs interact with Skyrizi?
• What drugs interact with Cosentyx?
• How Should Skyrizi Be Taken?
• How Should Cosentyx Be Taken?

Skyrizi (risankizumab-rzaa) and Cosentyx (secukinumab) are used to treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Skyrizi and Cosentyx are interleukin antagonists that target different proteins. Skyrizi is an interleukin-23 antagonist and Cosentyx is an interleukin-17A antagonist.

Side effects of Skyrizi and Cosentyx that are similar include upper respiratory infections and tinea infections (such as ringworm, athlete's foot, and jock itch).

Side effects of Skyrizi that are different from Cosentyx include headache, fatigue, and injection site reactions (bruising, redness, fluid leakage, bleeding, infection, inflammation, irritation, pain, itching, swelling, warmth).

Side effects of Cosentyx that are different from Skyrizi include sore throat and nose, diarrhea, stuffy or runny nose, oral herpes, hives, tonsillitis, oral thrush, impetigo, inflammatory bowel disease, ear infection, eye infection or inflammation (conjunctivitis), increased liver transaminases, and low white blood cell count (neutropenia).

Both Skyrizi and Cosentyx may interact with "live" vaccines.

Cosentyx may also interact with warfarin and cyclosporine.

Side effects of Skyrizi include:

• upper respiratory infections,
• headache,
• fatigue,
• injection site reactions (bruising, redness, fluid leakage, bleeding, infection, inflammation, irritation, pain, itching, swelling, warmth), and
• tinea infections (such as ringworm, athlete's foot and jock itch)

Common side effects of Cosentyx include:

• sore throat and nose,
• diarrhea,
• upper respiratory tract infection,
• sinus infection (sinusisits),
• stuffy or runny nose,
• oral herpes,
• hives,
• athlete's foot,
• tonsillitis,
• oral thrush,
• impetigo,
• inflammatory bowel disease,
• ear infection,
• eye infection or inflammation (conjunctivitis),
• increased liver transaminases, and
• low white blood cell count (neutropenia).

Skyrizi (risankizumab-rzaa) is an interleukin-23 antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Cosentyx (secukinumab) for Injection is a human interleukin-17A antagonist used to treat moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

Skyrizi may interact with "live" vaccines. Tell your doctor all medications and supplements you use and all vaccines you recently received. Tell your doctor if you are pregnant or plan to become pregnant before using Skyrizi; it is unknown how it would affect a fetus. It is unknown if Skyrizi passes into breast milk. Consult your doctor before breastfeeding.

Cosentyx may interact with abatacept, anakinra, warfarin, cyclosporine, theophylline, and live vaccines.

The dose of Skyrizi is 150 mg (two 75 mg injections) administered by subcutaneous injection at Week 0, Week 4 and every 12 weeks thereafter.

The recommended dose of Cosentyx is 300 mg by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. Each 300 mg dose is given as 2 subcutaneous injections of 150 mg.